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Background: A recent study from our laboratory showed that induction of the multidrug resistance related
drug efflux pump ABCG2 contributed to acquired resistance of human T cells to the disease modifying
antirheumatic drug (DMARD) sulfasalazine (SSZ).
Objectives: To investigate the duration of SSZ resistance and ABCG2 expression after withdrawal of SSZ
and rechallenging with SSZ, and to assess the impact of SSZ resistance on responsiveness to other
DMARDs.
Methods: Human CEM cells (T cell origin) with acquired resistance to SSZ (CEM/SSZ) were characterised
for (a) SSZ sensitivity and ABCG2 expression during withdrawal and rechallenge of SSZ, and (b)
antiproliferative efficacy of other DMARDs.
Results: ABCG2 protein expression was stable for at least 4 weeks when CEM/SSZ cells were grown in the
absence of SSZ, but gradually declined, along with SSZ resistance levels, to non-detectable levels after
withdrawal of SSZ for 6 months. Rechallenging with SSZ led to a rapid (,2.5 weeks) resumption of SSZ
resistance and ABCG2 expression as in the original CEM/SSZ cells. CEM/SSZ cells displayed diminished
sensitivity to the DMARDs leflunomide (5.1-fold) and methotrexate (1.8-fold), were moderately more
sensitive (1.6–2.0 fold) to cyclosporin A and chloroquine, and markedly more sensitive (13-fold) to the
glucocorticoid dexamethasone as compared with parental CEM cells.
Conclusion: The drug efflux pump ABCG2 has a major role in conferring resistance to SSZ. The collateral
sensitivity of SSZ resistant cells for some other (non-related) DMARDs may provide a further rationale for
sequential mono- or combination therapies with distinct DMARDs upon decreased efficacy of SSZ.
A
cquired drug resistance is recognised as a common
cause of treatment failure for patients with cancer after
sustained treatment with cytostatic drugs.1 2 An
important mechanism of acquired cellular drug resistance
to anticancer drugs is the overexpression of drug efflux
pumps belonging to the superfamily of adenosine triphos-
phate dependent binding cassette (ABC) transporters.2–6 ABC
transporters with an established role in drug efflux and drug
resistance include (a) P-glycoprotein (Pgp, ABCB1), which
confers resistance preferentially to lipophilic drugs7; (b)
members of the multidrug resistance associated protein
subfamily (MRP1-6, ABCC1-6), which confer resistance to
various anionic charged/glutathione conjugated drugs such
as methotrexate (MTX),8 thiopurines,9 10 and steroids5 11; and
(c) ABCG2, also known as breast cancer resistance protein
(BCRP), a recently identified ABC transporter that confers
resistance to amphiphilic drugs, including mitoxantrone and
MTX.12 13
In clinical rheumatology, loss of drug efficacy is also
noted for patients with rheumatoid arthritis (RA) receiving
long term treatment with disease modifying antirheumatic
drugs (DMARDs).14–17 Whether this loss of DMARD efficacy
is related to the onset of acquired resistance to DMARDs,
with mechanisms similar to anticancer drug resistance, is
not known.18 Meta-analyses of DMARD treatment termina-
tion rates showed that the DMARD sulfasalazine (SSZ)19 20
had a relatively shorter lasting efficacy than other DMARDs,
in particular the ‘‘gold standard’’ MTX.14 16–18 In general,
lack of efficacy may be related to diminished anti-
inflammatory and/or antiproliferative effects of DMARDs
against proinflammatory cytokine releasing cells at inflam-
matory sites.21
To gain insight into the possible mechanism(s) of
resistance to the antiproliferative/anti-inflammatory effects
of the DMARD SSZ, we previously provoked acquired
resistance to SSZ in an in vitro model system of human T
lymphocytes by stepwise exposure of CEM (T) cells to
gradually increasing concentrations of SSZ.22 This study
showed that SSZ resistance in CEM (T) cells was conferred
by overexpression of a drug efflux pump—notably, the
multidrug resistance transporter ABCG2/BCRP. Owing to
enhanced drug efflux in SSZ resistant cells (CEM/SSZ),
higher concentrations of SSZ were required to inhibit the
secretion of the proinflammatory cytokine tumour necrosis
factor a (TNFa).22
In the present study we investigated the stability of the
resistant phenotype of CEM/SSZ cells after withdrawal of SSZ
in order to establish whether SSZ resistance is slowly/rapidly
lost over time and reinducible after SSZ rechallenge.
Moreover, we analysed to what extent SSZ resistance affected
antiproliferative effects of other DMARDs and anti-inflam-
matory drugs. The results demonstrated that SSZ resistance,
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along with ABCG2 expression, was gradually lost over a
period of 6 months after withdrawal of SSZ, but rapidly re-
emerged, within 2 weeks, upon rechallenge with SSZ. Drug
sensitivity was as follows: CEM/SSZ cells displayed lower
sensitivity (fivefold) to the DMARD leflunomide, a slightly
diminished sensitivity to MTX (twofold), moderately
increased sensitivities for cyclosporin A and chloroquine
(up to twofold), but a markedly enhanced sensitivity for
dexamethasone (13-fold).
MATERIALS AND METHODS
Materials
Sulfasalazine, leflunomide, chloroquine, phenylmethyl-
sulfonyl fluoride (PMSF), and dexamethasone were pur-
chased from Sigma Chemical Co (St Louis, MO, USA).
Protease inhibitor cocktail and Triton X-100 were from
Boehringer Mannheim (Ingelheim, Germany). MG132 was
from Calbiochem (Germany). MTX was a generous gift from
Pharmachemie Haarlem, the Netherlands. Cyclosporin A was
a gift from Novartis (Arnhem, the Netherlands). The ABCG2
inhibitor Ko14323 was kindly provided by Dr A Schinkel
(Netherlands Cancer Institute, Amsterdam, the
Netherlands). RPMI-1640 tissue culture medium and fetal
calf serum (FCS) were obtained from Gibco Chemical Co,
Grand Island NY, USA.
Cell culture and selection of SSZ resistant CEM (T) cells
SSZ resistant human CEM (T) cells were isolated as described
previously.22 In short, human CEM (T) cells were cultured at
an initial density of 36105 cells/ml in RPMI-1640 medium
supplemented with 10% FCS, 2 mM L-glutamine, and
100 mg/ml penicillin and streptomycin in a 5% CO2 incubator
at 37 C˚.24 25 Cell cultures were refreshed twice weekly and SSZ
was added to the cell culture medium at an initial
concentration of 0.4 mmol/l. This concentration of SSZ could
be stepwise increased to 1.5 mM SSZ (after 4 months) and
2.5 mM SSZ after a period of 6 months.
Extensive binding of SSZ to plasma proteins (serum
albumin) is known to limit its therapeutic effect.26 27 Based
on the presence of at least three classes of SSZ binding sites
on serum albumin and their association rate constants28 it
can be calculated that a protein concentration of about
100 mmol/l in 10% FCS can bind 320 mM SSZ. For the two
selected SSZ resistant CEM cells grown in the presence of 1.5
and 2.5 mM SSZ, this would imply that 21% and 13% of SSZ,
respectively, is protein bound.
It should be recognised that CEM cells are of T cell
leukaemic origin, proliferating with a doubling time of 26–
30 hours. Thus CEM cells may not fully representative for
normal T cells or T cells applicable to RA. However, CEM cells
may serve as a valuable in vitro model system for RA research
as they respond to T cell stimuli, producing proinflammatory
cytokines like TNFa.22 Furthermore, CEM cells have been
exploited to disclose resistance mechanisms to MTX that are
clinically encountered.24 29–31
Antiproliferative effects of DMARDs and other drugs were
analysed by plating 1.256105 cells/ml of parental CEM (T)
cells, CEM/SSZ1.5, and CEM/SSZ2.5 cells (in the absence of
SSZ) in individual wells of a 24 well plate containing up to
50 ml of drug solution. Inhibition of cell growth was
determined after 72 hours’ incubation by counting cells with
a haemocytometer and cell viability by trypan blue exclusion.
The drug concentration required to inhibit cell growth by 50%
compared with control growth is defined as the IC50
concentration.
Western blotting
For analysis of expression of ABCG2/BCRPand ABCC1/MRP1,
cells were harvested in the mid-log phase of growth and
washed three times with ice cold Hepes buffered saline,
pH 7.4. Total cell lysates of 107 cells were suspended in 500 ml
of lysis buffer containing 50 mM Tris-HCl (pH 7.6), 5 mM
dithiothreitol, 20 ml protease inhibitor cocktail (one tablet/ml
H2O), 20% glycerol, and 0.5% NP-40. The suspension was
sonicated (MSE sonicator, amplitude 6, for 365 seconds with
30 seconds time intervals at 4 C˚) and centrifuged in an
Eppendorf microcentrifuge (10 minutes, 14 000 rpm, 4 C˚).
Protein content of the supernatant was determined by Biorad
protein assay.32 Fifty microgram of total cell lysates was
fractionated on a 7.5% polyacrylamide gel and transferred
onto a nitrocellulose membrane. The nitrocellulose mem-
branes were preincubated overnight at 4 C˚ in blocking buffer
(5% Biorad Blocker in TBS-T (10 mM Tris-HCl, pH 8.0,
0.15 M NaCl, 0.1% Tween-20) to prevent aspecific antibody
binding. After blocking, the membranes were incubated for
1 hour at room temperature with the primary antibodies for
the multidrug resistant (MDR) pumps ABCG2/BCRP (BXP21,
1:400) and MRP1 (MRPr1, 1:500) as described by Scheffer et
al.32 33 As control for protein loading, b-actin (Chemicon
International, Ca, USA: 1:3000) was used. After three
washing steps with TBS-T, membranes were incubated for
1 hour with horseradish peroxidase labelled antirat/mouse
(Dako; 1:2000 for ABCG2/BCRP and ABCC1/MRP1, and
1:3000 for b-actin) as secondary antibody. Detection of the
antibody binding was measured by enhanced chemilumines-
cence according to the manufacturer’s instructions
(Amersham International, Buckinghamshire, UK). Protein
levels were determined by densitometric scanning (GelDoc
and Molecular Analyst, Biorad Laboratories) of the x ray films
(Hyperfim ECL, Amersham International, Buckinghamshire,
UK).
Statistical analysis
Statistical significance of differences was analysed by
analysis of variance using SPSS 9.0 computer software. A p
value ,0.05 was considered to be significantly different.
RESULTS
Onset and stability of SSZ resistance in human CEM (T)
cells
Acquired resistance to SSZ in human CEM (T) cells could be
provoked by culturing cells in stepwise increasing concentra-
tions of SSZ.22Figure 1A (point A) shows the antiproliferative
effect of SSZ (IC50: concentration for 50% growth inhibition)
for CEM (T) cells at the initial dosing of 0.4 mM SSZ, and for
CEM (T) cells that were grown in the presence of stepwise
increasing concentrations of SSZ. After a period of 4 months,
CEM (T) could be maintained at an IC50 concentration of
1.5 mM SSZ (CEM/SSZ1.5) which was about fourfold higher
than parental CEM (T) cells. When CEM/SSZ1.5 cells were
grown in the presence of 1.5 mM SSZ for another 2 months,
the IC50 value slightly increased to 1.7 mM (fig 1A, point B).
When, in parallel, CEM/SSZ1.5 cells obtained after 4 months
were exposed to further increasing concentrations of SSZ for
2 months, eventually CEM/SSZ2.5 cells were obtained that
could grow in the presence of 2.5 mM SSZ (not shown).
To establish whether the SSZ resistance in CEM/SSZ1.5
cells is a transient or stable phenotype, CEM/SSZ1.5 cells (at
point B) were further grown in the absence of SSZ, and IC50
values for the CEM/SSZ1.5 cells were monitored over time.
After 1 week in the absence of SSZ, IC50 values for SSZ
dropped by 40–50% to stay at this level for up to 4 weeks.
From this point on, IC50 values for SSZ gradually declined to
reach ultimately the original levels of SSZ sensitivity of
parental CEM (T) cells (point C). To assess whether SSZ
resistance would be reinduced upon exposure to SSZ,
revertant CEM/SSZ1.5 cells were re-exposed to 1.5 mM
SSZ. Within only 2.5 weeks’ exposure to SSZ (D), revertant
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CEM/SSZ1.5 cells resumed their original level of SSZ
resistance as seen at point B. These results indicate that
although SSZ resistance in CEM/SSZ is transiently lost over a
period of 6 months, rechallenge of revertant cells with SSZ
rapidly reinduces resistance to SSZ.
Expression of MDR transporters ABCG2/BCRP and
ABCC1/MRP1 in CEM (T) and CEM/SSZ cells
Initial studies from our laboratory22 reported differential
expression of MDR proteins upon development of SSZ
resistance in CEM/SSZ cells: induction of ABCG2/BCRP and
down regulation of ABCC1/MRP1 expression. Figure 1B
illustrates the expression of ABCG2/BCRP and ABCC1/
MRP1 at the various times A–D in fig 1A. Parental CEM (T)
cells (point A, fig 1A) exhibited undetectable levels of
expression of ABCG2/BCRP protein, but had an appreciable
level of ABCC1/MRP1. In contrast, SSZ resistant CEM cells
isolated at 1.5 mM SSZ (CEM/SSZ1.5 cells) (fig 1A, point B)
showed a marked induction of ABCG2/BCRP expression and
down regulation of ABCC1/MRP1 expression. After with-
drawal of SSZ from the cell culture of CEM/SSZ1.5 for a
period of 6 months (fig 1A, point C) ABCG2/BCRP and
ABCC1/MRP1 expression reverted to the original levels of
parental CEM (T) cells. Notably, when revertant CEM/SSZ1.5
were re-exposed to 1.5 mM SSZ for 2.5 weeks (fig 1A, point
D), ABCG2/BCRP expression was rapidly up regulated, while
ABCC1/MRP1 was again down regulated. As a control,
fluctuations in the expression of ABCG2/BCRP paralleled
the growth inhibitory effects (IC50 values) for the cytostatic
drug mitoxantrone, which is a known substrate for efflux by
ABCG2/BCRP6 34 (data not shown).
Because fig 1A showed that changes in IC50 values for
CEM/SSZ1.5 cells were particularly noted within the first
10 weeks after withdrawal of SSZ (fig 1A, point BRC), we
fine tuned the analysis of IC50 values for SSZ and changes in
expression of ABCG2/BCRP and ABCC1/MRP1 during this
period of 10 weeks. IC50 values for SSZ dropped by about 40–
50% after growth of CEM/SSZ1.5 cells in the absence of SSZ
for 1 week (fig 2A). From this point on, IC50 values for SSZ
only slowly declined. At 70 days after withdrawal of SSZ
from CEM/SSZ1.5 cells, resistance to SSZ could still be noted
compared with parental CEM (T) cells. Figure 2B shows the
expression of ABCG2/BCRP and ABCC1/MRP1 in parental
CEM (T) cells (lane A) compared with CEM/SSZ1.5 cells
before (lane B) and after withdrawal of SSZ for 3 days,
7 days, 4 weeks, and 10 weeks (lanes C–F, respectively).
ABCG2/BCRP protein expression in CEM/SSZ1.5 cells
appeared to be stable for at least 4 weeks after withdrawal
of SSZ, after which a diminished, but still detectable, level of
expression could be seen after 10 weeks. ABCC1/MRP1
expression, which was down regulated in CEM/SSZ1.5 cells
in the presence of SSZ, was rapidly reinduced within 3–
7 days after withdrawal of SSZ, even overshooting the level
of ABCC1/MRP1 expression in parental CEM (T) cells after
70 days of SSZ withdrawal from CEM/SSZ1.5 cells. These
results indicate that ABCG2/BCRP and ABCC1/MRP1 follow
an inverse pattern of expression after SSZ exposure/with-
drawal.
Given the apparent discrepancy of the rapid partial loss of
SSZ resistance within 1 week of withdrawal of SSZ from
CEM/SSZ1.5 cells (fig 2A) and the stable expression of
ABCG2/BCRP during this period (fig 2B, lanes B–D), we
further investigated the functional contribution of ABCG2/
BCRP in SSZ resistance by blocking ABCG2/BCRP with a
specific inhibitor, Ko143.23 Blocking of ABCG2/BCRP reversed
SSZ resistance in CEM/SSZ1.5 cells by 50–60%, but not
completely, to parental CEM (T) cell sensitivity (fig 2C). After
growth of CEM/SSZ1.5 cells in the absence of SSZ for
4 weeks, when IC50 values for SSZ had stabilised at about
50% of the original CEM/SSZ1.5 cells, Ko143 fully reversed
the residual SSZ resistance of CEM/SSZ1.5 cells to the SSZ
sensitivity of CEM (T) cells (fig 2C). These results indicate
that SSZ resistance in CEM/SSZ1.5 is mediated by at least
two components, each contributing about 50%. One compo-
nent, is rapidly lost within one week after withdrawal of SSZ,
the other component, which stabilised after 1–4 weeks’
growth of CEM/SSZ1.5 cells in the absence of SSZ, can be
fully accounted for by ABCG2/BCRP. The latter component is
then gradually lost over period of 5 months’ culture in the
absence of SSZ.
Sensitivity profile of CEM/SSZ cells for DMARDs and
other anti-inflammatory drugs
In clinical rheumatology, SSZ is applied sequentially in
mono- and/or combination therapies with other
DMARDs.19 35 20 For this reason, we investigated whether
the onset of SSZ resistance affects the sensitivity for other
clinically active DMARDS, as well as other drugs with
Figure 1 (A) Time course of sensitivity to sulfasalazine (SSZ) of CEM (T)
during development of SSZ resistance, after withdrawal of SSZ from
CEM/SSZ1.5 cells and rechallenge of revertant CEM/SSZ1.5 cells with
SSZ. Parental CEM (T) cells (point A) were exposed to a starting
concentration of 0.4 mM SSZ that was gradually increased to 1.5 mM
over a period of 6 months to yield SSZ resistant CEM/SSZ1.5 cells (point
B). From this point on CEM/SSZ1.5 were grown in the absence of SSZ to
finally yield revertant CEM/SSZ1.5 cells that displayed again parental
CEM (T) cell sensitivity to SSZ (point C). When revertant cells were re-
exposed to 1.5 mM SSZ for 2.5 weeks (point D), CEM/SSZ1.5 resumed
their original resistance level as observed at point B. IC50 values were
determined after 72 hours’ exposure of cells to SSZ. (B) ABCG2/BCRP
and ABCC1/MRP1 protein expression, and mitoxantrone sensitivity of
CEM (T) cells and (revertant) CEM/SSZ1.5 cells isolated at the various
time points A–D. Cell lysates of 2008/MRP132 and MCF7/MR43 served
as positive controls for ABCC1/MRP1 and ABCG2/BCRP, respectively
(not shown). For CEM (T) and CEM/SSZ1.5 cells, 50 mg of total cell
lysate was applied on the sodium dodecyl sulphate polyacrylamide gel,
and for the controls 10 mg protein. ABCC1/MRP1 was detected by the
monoclonal antibody MRPr1, and ABCG2/BCRP was detected by the
monoclonal antibody BXP21.32 33 b-Actin was used as a control for equal
protein loading.
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potentially anti-inflammatory properties. Drug sensitivities
were evaluated by their antiproliferative effects for CEM/
SSZ1.5 and CEM/SSZ2.5 cells as compared with parental
CEM (T) cells (table 1).
Cross resistance to mitoxantrone, a topoisomerase II
inhibitor that is a prototypical substrate for ABCG2/
BCRP34 36 for both CEM/SSZ1.5 (4.3-fold, p = 0.002 v CEM )
and CEM/SSZ2.5 cells (6.4-fold, p,0.001 v CEM), was
studied. As expected, mitoxantrone cross resistance was fully
reversed by the ABCG2/BCRP blocker Ko143. Furthermore,
cross resistance of CEM/SSZ cells was noted for the DMARDs
leflunomide (up to 5.1-fold for CEM/SSZ2.5, p = 0.005 v
CEM) and MTX (up to 1.8-fold for CEM/SSZ2.5, p = 0.027 v
CEM). Because SSZ mediates part of its anti-inflammatory
effects by targeting the NFkB signalling pathway,37 38 we also
determined the drug sensitivity for MG132, an inhibitor of
NFkB activation through inhibition of 26S-proteasome.39 A
low level of cross resistance for CEM/SSZ cells was noted for
MG132 (1.6-fold, p = 0.004 for CEM/SSZ2.5 and p,0.001 for
CEM/SSZ1.5 v CEM). Interestingly, enhanced sensitivity of
CEM/SSZ cells was noted for the DMARDs chloroquine (up to
1.9-fold CEM/SSZ2.5, p = 0.043 v CEM) and cyclosporin A
(up to 1.6-fold, p(0.001 for CEM/SSZ1.5 and p = 0.028 for
CEM/SSZ2.5 v CEM). CEM/SSZ cells displayed even more
hypersensitivity (up to 13-fold, p = 0.002 for CEM/SSZ1.5
and p = 0.003 for CEM/SSZ2.5 v CEM) to the glucocorticoid
dexamethasone. These results indicate that induction of SSZ
resistance can coincide with a differentially altered DMARD
sensitivity pattern, including, on the one hand, cross
resistance to leflunomide and MTX, but on the other,
enhanced sensitivity to cyclosporin A and chloroquine, and,
most notably, to dexamethasone.
DISCUSSION
Characterisation of human CEM (T) cells with acquired
resistance to the DMARD SSZ showed differential expression
of two MDR efflux pumps: up regulation of ABCG2/BCRP
and down regulation of ABCC1/MRP1. This phenotype could
be reverted (slowly) and reinduced (rapidly) after SSZ
withdrawal and SSZ re-exposure, respectively. Beyond this,
CEM/SSZ cells were characterised by enhanced sensitivity to
the DMARDs cyclosporin A and chloroquine, and most
notably to dexamethasone, which may provide possible
strategies to circumvent resistance to SSZ.
SSZ is commonly used in various DMARD regimens for RA
treatment, including monotherapy or combination therapy
with other DMARDs such as MTX, hydroxychloroquine or in
the COBRA regimen.19 20 35 40 SSZ can induce antiproliferative/
Figure 2 (A) Antiproliferative effect of SSZ against CEM/SSZ1.5 cells isolated at various times (0–10 weeks) after withdrawal of SSZ from CEM/
SSZ1.5 cells from point B in fig 1A: 0 days (closed circles), 3 days (open triangles), 1 week (closed triangles), 4 weeks (open diamonds), 10 weeks
(closed squares). Antiproliferative effects/growth inhibition for SSZ were evaluated after 72 hours’ exposure to SSZ and compared with those for
parental CEM (T) cells (open circles). (B) Expression of ABCG2/BCRP and ABCC1/MRP1 protein of CEM/SSZ1.5 cells during withdrawal of SSZ for up
to 10 weeks as in fig 2A. Lane A: parental CEM (T) cells; lane B: CEM/SSZ1.5 cells before withdrawal of SSZ; lanes C–F: CEM/SSZ1.5 cells 3 days, 7
days, 4 weeks, and 10 weeks, respectively, after withdrawal of SSZ. Note: sample E for ABCC1/MRP1 was not tested. (C) Reversal of SSZ resistance in
CEM/SSZ1.5 cells by the ABCG2/BCRP blocker Ko143 before and after 4 weeks’ withdrawal of SSZ. Symbols: (open triangle) parental CEM (T) cells,
(open circles) CEM/SSZ1.5 cells, (closed circles) CEM/SSZ cells + 0.5 mM Ko143, (open squares) CEM/SSZ1.5 cells after 4 weeks’ withdrawal of
SSZ, (closed squares) CEM/SSZ1.5 cells after 4 weeks withdrawal of SSZ + 0.5 mM SSZ. Antiproliferative effects of SSZ were evaluated after
72 hours’ exposure to SSZ in the absence or presence of Ko143.
Table 1 Antiproliferative effects of DMARDs and other drugs against CEM (T) and CEM/
SSZ cells
DMARD/drug
IC50[RF]`
CEM (T) CEM/SSZ1.5 CEM/SSZ2.5
SSZ (mM) 400 (30) [1] 1720 (170) [4.3]*** 2550 (212) [6.4]***
Mitoxantrone (nM) 0.47 (0.08) [1] 1.94 (0.67) [4.1]** 3.3 (0.6) [7.0]***
Mitoxantrone (+Ko143)1 0.33 (0.07) [1] 0.36 (0.06) [1.1] ND
Leflunomide (mM) 17.2 (1.9) [1] 37.4 (14.4( [2.2]NS 88.0 (37.4) [5.1]**
Methotrexate (nM) 8.4 (0.7) [1] 9.0 (0.7) [1.1]NS 15.1 (5.1) [1.8]*
MG132 (nM) 39.5 (5.0) [1] 68.1 (8.8) [1.7]*** 63.1 (7.9) [1.6]**
Chloroquine (mM) 44.5 (7.5) [1] 37.8 (8.7) [0.8]NS 23.3 (13.9) [0.5]*
Cyclosporin A (mM) 5.7 (0.8) [1] 3.6 (0.8) [0.6]** 4.0 (0.2) [0.7]*
Dexamethasone (nM) 41.5 (13.1) [1] 3.4 (0.6) [0.08]** 6.4 (0.8) [0.15]**
Statistical significance (analysis of variance test): IC50 CEM/SSZ v IC50 CEM (T): *p,0.05; **p,0.01;
***p,0.001; NS, not significant.
IC50 values were determined after 72 hours of DMARD/drug exposure. Values are mean (SD) of 3–6 separate
experiments; `(RF), resistance factor: IC50 CEM/SSZ:IC50 CEM (T); 1100 nM Ko143.
ND, not determined.
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apoptotic effects41 as well as anti-inflammatory effects by
inhibiting activation of NFkB,37 which leads to the decreased
production/secretion of proinflammatory cytokines such as
TNFa.38 Although SSZ is a potent DMARD, its efficacy in long
term treatment seems to be more compromised than that of
other DMARDs, such as MTX.14 16 18 Because lack of efficacy
may be related to either persistent/renewed disease activity
and/or side effects of DMARDs, we suggested that dimin-
ished SSZ efficacy might also be associated with the
development of resistance. Indeed, as previously reported,22
we found that the onset of SSZ resistance in human CEM (T)
cells coincided with the induction of the MDR pump ABCG2/
BCRP. Thus far, ABCG2/BCRP induction had only been noted
upon development of a selected group of topoisomerase
inhibitors such as mitoxantrone, doxorubicin, and topote-
can.12 34 42–44
ABCG2/BCRP expression in CEM/SSZ cells did not fully
account for the resistant phenotype as about 50% of the SSZ
resistance was lost within one week after withdrawal of SSZ,
whereas ABCG2/BCRP expression was unchanged. The
nature of this latter component has not been identified, but
may be related to SSZ-induced transient alterations in the
NFkB signalling pathway38 that controls the transcription of
anti-apoptotic and proinflammatory cytokine/chemokine
genes.45–47 Consistent with this hypothesis is the observation
of a two- to threefold enhancement of TNFa production/
secretion by CEM/SSZ cells compared with CEM (T) cells.22 It
remains to be established whether this type of SSZ
resistance-induced effect may also be responsible for the
altered antiproliferative effects (table 1) of NFkB signalling
pathway drugs, including leflunomide,48 MG132,39 and
dexamethasone.45 49 50
The gradual loss of ABCG2/BCRP expression from cell
cultures of CEM/SSZ1.5 cells after 6 months’ (approximately
50 passages) withdrawal of SSZ is consistent with a study by
Maliepaard et al, who noted the loss of ABCG2/BCRP
expression from a topotecan resistant ovarian carcinoma cell
line over 30 passages in drug-free medium.51 These results
indicate that ABCG2/BCRP expression gradually declines
when the selective pressure is absent, but can be rapidly
resumed upon renewed exposure to the selective drug.
Besides the effects on ABCG2/BCRP expression, it is of
interest to note that SSZ exposure/resistance had down
regulatory effects on the expression of ABCC1/MRP1.
Although this MDR transporter has an established role in
extrusion of various toxic drugs,2 5 11 it also has important
immunological functions in, for instance, dendritic cells,
where, by exporting the cysteinyl leucotriene LTC4, it
mediates the signalling for chemokine CCL19 chemotaxis
and migration of dendritic cells to the lymph nodes.52 Because
SSZ is an inhibitor of LTC synthetase,53 impaired synthesis of
LTC may parallel reduced expression of its transporter
ABCC1/MRP1. Another example of ABCC1/MRP1 down/up
regulation was recently identified by our laboratory after
depletion/repletion of cellular folate status54 in CEM (T) cells.
Consistent with the notion that SSZ can also exert antifolate
effects,55 we obtained preliminary evidence that the differ-
ential expression of ABCC1/MRP1 is indeed correlated with
the cellular folate status in CEM/SSZ cells (Jansen G, Scheper
RJ, Dijkmans BAC, unpublished data).
The present study also provides insight into strategies that
may or may not be successful to circumvent/reverse SSZ
resistance. Firstly, temporary discontinuation of DMARD
treatment after an initial response and resumption of the
treatment at the time of progressive disease proved to be
effective.56 Whether a similar strategy is also effective for
patients with RA for whom DMARD treatment has failed, has
not been investigated. When such a clinical strategy was
mimicked in vitro—discontinuation of SSZ treatment after
development of SSZ resistance and rechallenging with SSZ at
the time SSZ resistance had apparently disappeared—it did
not seem to be effective. SSZ resistance, along with ABCG2/
BCRP overexpression, was rapidly reinduced (,2.5 weeks).
Secondly, development of resistance to SSZ may be accom-
panied by adverse effects of collateral resistance to other
DMARDs (for example, leflunomide) which might be used
for sequential monotherapy. Potentially positive strategies to
target SSZ resistance may include the use of (a) blockers of
ABCG2/BCRP that serve as chemosensitisers to reverse SSZ
resistance (for example, Ko143); (b) DMARDs whose
antiproliferative activity was not impaired during develop-
ment of SSZ resistance, such as cyclosporin A and chloro-
quine. Because chloroquine is a substrate for efflux by
ABCC1/MRP1, a reduced expression of ABCC1/MRP1, as seen
in CEM/SSZ cells, may confer enhanced sensitivity to
chloroquine,57 which could increase the efficacy of hydroxy-
chloroquine containing treatments.20 Finally, most interest-
ing was the observation that CEM/SSZ cells displayed
hypersensitivity (13-fold) to the glucocorticoid dexametha-
sone. One previous report has described collateral sensitivity
to dexamethasone (10-fold) in human myeloma cells with
acquired resistance to doxorubicin.58 The mechanistic basis
for the markedly enhanced dexamethasone sensitivity is not
clear, but is not associated with an increase in glucocorticoid
receptor levels in CEM/SSZ cells compared with CEM (T) cells
(not shown).
Altogether, this study shows that exposure/resistance to
SSZ can have differential effects on the expression of at least
two important MDR pumps: ABCG2/BCRP and ABCC1/
MRP1. As these MDR pumps are normally expressed on
various peripheral blood cell types,59–61 further research is
warranted to identify the expression levels of these MDR
pumps during treatment of patients with RA with DMARDs
which include SSZ. Thus far, only a few studies have
investigated blood samples of patients with RA for differ-
ential expression of the MDR transporter Pgp.62–65 Although
these studies included limited numbers of patients, data were
supportive for a role of Pgp in DMARD efficacy. Our present
study, though based on in vitro data using a T cell model
system, demonstrates also that MDR pumps other than Pgp
may be relevant for DMARD resistance. Once specific MDR
proteins are identified for their contributing role in DMARD
(in)efficacy, this information may be exploited to use specific
blockers for the various MDR pumps2 as chemosensitisers for
DMARD activity.
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